Fabrication of Bioconjugates Clacked Chitosan‐Coated SN‐38 Liposomal Nanoparticles: Improved Precise Chemotherapy Efficacy in Lung Cancer Cells and Its Apoptosis.
Saved in:
| Title: | Fabrication of Bioconjugates Clacked Chitosan‐Coated SN‐38 Liposomal Nanoparticles: Improved Precise Chemotherapy Efficacy in Lung Cancer Cells and Its Apoptosis. |
|---|---|
| Authors: | Zhang, Xiaojun1 (AUTHOR), Sun, Wei1 (AUTHOR), Liu, Changting1 (AUTHOR) changtingbio@outlook.com |
| Source: | Biotechnology & Applied Biochemistry. Oct2025, Vol. 72 Issue 5, p1302-1312. 11p. |
| Subjects: | Lung cancer, Targeted drug delivery, Chitosan, Cancer chemotherapy, HER2 protein, Liposomes, Apoptosis, Bioconjugates |
| Abstract: | Employing an active targeting method with monoclonal antibodies for chemotherapeutics‐loaded nanocarriers represents a promising option to enhance the specific drug delivery and alleviate the detrimental effects of chemotherapeutic agents. Targeted delivery to the human epidermal growth factor receptor‐2 (HER2), which is overexpressed in HER2+ lung cancerous cells, can be accomplished by conjugating nanoparticles with a monoclonal antibody (anti‐HER2). We developed trastuzumab (TZ)‐conjugated chitosan iodoacetamide (CsIA)‐coated liposomal nanoparticles carrying SN‐38 (TZ‐SN‐CsIA LNPs) as a lung‐targeted delivery. CsIA was used to develop trastuzumab‐clacked nanoparticles (TZ LNPs). The structure, physicochemical characteristics, SN‐38 encapsulation, SN‐38 release, and anticancer properties of the LNPs were established. The TZ LNPs were spherical, measuring around 77 nm in diameter, and exhibited a positive zeta potential; upon drug incorporation, the diameter of the TZ LNPs enlarged. A sustained, 24‐h SN‐38 release from the nanocarriers was accomplished. TZ LNPs demonstrated substantial cellular accumulation and markedly enhanced anticancer efficacy against HER2+ Calu‐3 lung adenocarcinoma cancer cells compared to the drug solution and unconjugated LNPs. Consequently, TZ‐SN‐CsIA LNPs may be a potential nanocarrier for HER2+ lung cancer. [ABSTRACT FROM AUTHOR] |
| Copyright of Biotechnology & Applied Biochemistry is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Engineering Source |
|
Full text is not displayed to guests.
Login for full access.
|
|
| Abstract: | Employing an active targeting method with monoclonal antibodies for chemotherapeutics‐loaded nanocarriers represents a promising option to enhance the specific drug delivery and alleviate the detrimental effects of chemotherapeutic agents. Targeted delivery to the human epidermal growth factor receptor‐2 (HER2), which is overexpressed in HER2+ lung cancerous cells, can be accomplished by conjugating nanoparticles with a monoclonal antibody (anti‐HER2). We developed trastuzumab (TZ)‐conjugated chitosan iodoacetamide (CsIA)‐coated liposomal nanoparticles carrying SN‐38 (TZ‐SN‐CsIA LNPs) as a lung‐targeted delivery. CsIA was used to develop trastuzumab‐clacked nanoparticles (TZ LNPs). The structure, physicochemical characteristics, SN‐38 encapsulation, SN‐38 release, and anticancer properties of the LNPs were established. The TZ LNPs were spherical, measuring around 77 nm in diameter, and exhibited a positive zeta potential; upon drug incorporation, the diameter of the TZ LNPs enlarged. A sustained, 24‐h SN‐38 release from the nanocarriers was accomplished. TZ LNPs demonstrated substantial cellular accumulation and markedly enhanced anticancer efficacy against HER2+ Calu‐3 lung adenocarcinoma cancer cells compared to the drug solution and unconjugated LNPs. Consequently, TZ‐SN‐CsIA LNPs may be a potential nanocarrier for HER2+ lung cancer. [ABSTRACT FROM AUTHOR] |
|---|---|
| ISSN: | 08854513 |
| DOI: | 10.1002/bab.2740 |
